Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CASP2 | P42575 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24340761 | 0.86 | FAAH (0.51) | FAAHHSP90AA1DNM1GAACASP2 | |
| SCHEMBL11245690 | 0.84 | FAAH (0.50) | FAAHHSP90AA1DNM1RECQLGAA | |
| SCHEMBL26034080 | 0.82 | FAAH (0.47) | FAAHHSP90AA1DNM1GAACASP2 | |
| SCHEMBL11242257 | 0.81 | FAAH (0.58) | FAAHHSP90AA1DNM1CASP2CNR1 | |
| SCHEMBL21096814 | 0.81 | FAAH (0.46) | FAAHHSP90AA1DNM1GAACASP2 | |
| SCHEMBL25849461 | 0.80 | FAAH (0.56) | FAAHHSP90AA1DNM1RECQLGAA | |
| SCHEMBL26042666 | 0.80 | DNM1 (0.43) | FAAHHSP90AA1DNM1RECQLGAA | |
| SCHEMBL26789160 | 0.79 | MEN1 (0.40) | RECQLMEN1KMT2A | |
| SCHEMBL13701833 | 0.79 | FAAH (0.64) | FAAHHSP90AA1DNM1GAACASP2 | |
| SCHEMBL24341855 | 0.79 | FAAH (0.44) | FAAHDNM1CASP2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | FAAH 2901/4885HSP90AA1 1924/4885DNM1 376/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | FAAH 4742/4885HSP90AA1 919/4885DNM1 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.